This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Topic Collections  • Men's Health  • Prostate Disease  • Oncology  • Prostate Cancer  • Surgery  • Surgical Interventions  • Urology  • Screening  • Alert me on articles by topic  Social Bookmarking   What's this?

Mike Mitka

JAMA. 2009;301(24):2538-2539.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Chicago—The controversy swirling around the appropriateness of screening for prostate cancer may have become even more controversial.

At the annual meeting of the American Urological Association (AUA), held here in April, the association released an updated "best practice" statement that calls for offering early detection of and risk assessment for prostate cancer to all asymptomatic men at age 40 years with an estimated life expectancy of more than 10 years. This process would involve determining a baseline prostate-specific antigen (PSA) level to help physicians and patients develop a strategy for monitoring prostate cancer risk. Depending on the baseline reading, such a strategy might involve annual PSA testing and digital rectal examination (DRE) or more infrequent testing (http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines/main-reports/psa09.pdf).

Controversy surrounding the appropriateness of prostate cancer screening for asymptomatic men is reflected in the wide divergence of recommendations for such testing by policy-making groups.

However, the AUA's . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?